Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Atypical Ductal Hyperplasia|Breast Atypical Lobular Hyperplasia|Breast Ductal Carcinoma In Situ|Breast Lobular Carcinoma In Situ|Invasive Breast Carcinoma
Interventions: DRUG: Bexarotene|OTHER: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)